VBI Vaccines hopes to challenge the hepatitis B vaccine standard-of-care, a position long held by GlaxoSmithKline’s Engerix-B.
Emergent BioSolutions has snapped up the only FDA-approved smallpox vaccine from Sanofi Pasteur.
GlaxoSmithKline plans to explore MenB vaccine Bexsero's potential in preventing gonorrhea after a new study suggested plausible protection.
Using a painless microneedle patch, scientists are trying to take the "Ow!" out of flu shots.
While GSK is still expected to top the vaccine industry in 2022, rankings for other players have shifted in Evaluate's new World Preview.
Chasing a $6 billion market opportunity, Bavarian Nordic reports that a dose of its universal RSV vaccine can elicit a significant immune response.
Six senators are railing on Sanofi for its role in a Zika pricing dustup that’s gained considerable attention since last year.
The EU's highest court ruled that EU national courts don't need scientific proof to consider a vaccine as defect.
Declining sales of Prevnar have urged Pfizer to seek compensation elsewhere, including a vaccine against Group B streptococcus.
BiondVax secured a €20 million loan from the European Investment Bank to advance its universal flu vaccine candidate.